LAUSR

Hodgkin lymphoma (HL), accounting for ~10% of lymphomas diagnosed in the United States (1), have a largely favorable outcome (5-year survival 85%) that may be improved with anti-CD30-drug conjugates or checkpoint inhibitors (2, 3). However, relapsed/ refractory HL has poor outcomes and necessitates intensive salvage chemotherapy and/or autologous hematopoietic cell transplantation (4). Factors classifying HL relapse/refractory risk are needed for determining optimal treatment strategies (5). Therefore, identifying key factors underlying the mechanisms of HL cell survival and maintenance are necessary to uncover new therapeutic targets and/or develop innovative strategies to increase cure rates and long-term disease control while limiting toxicities in HL patients.